Zobrazeno 1 - 10
of 51
pro vyhledávání: '"G. E. Janka-Schaub"'
Publikováno v:
Leukemia. 24:298-308
In this study, the long-term outcome of 1818 patients treated in five consecutive clinical trials (the cooperative study group for childhood acute lymphoblastic leukaemia (COALL) 82, 85, 89, 92 and 97) from 24 cooperating centres in Germany is report
Autor:
Ulrich Göbel, Birgit Ackermann, L Glouchkova, Dagmar Dilloo, Gabriele Escherich, Helmut Hanenberg, G. E. Janka-Schaub, Meinolf Siepermann, Anja Troeger
Publikováno v:
Klinische Pädiatrie. 220:353-357
BACKGROUND: There is a subgroup of pediatric patients with an immature immunophenotype of proB-ALL that still poses a therapeutic challenge, even if the overall prognosis in B cell precursor acute lymphoblasic leukemia (BCP-ALL) is very good. Due to
Autor:
G. E. Janka-Schaub, R. X de Menezes, W A G Stams, E. R. Van Wering, M L den Boer, Rob Pieters, A. H. Loonen, E van Drunen, N L Ramakers-van-Woerden, R L Stigter, H B Beverloo
Publikováno v:
Leukemia, 20, 410-416. Nature Publishing Group
Clinical heterogeneity within t(12;21) or TEL/AML1-positive ALL (25% of childhood common/preB ALL) indicates that additional genetic changes might contribute to outcome. We studied the relation between additional genetic changes in TEL(ETV6) and AML1
Autor:
M. Meier, Jules P.P. Meijerink, Rob Pieters, M L den Boer, Mathilde J.C. Broekhuis, E. R. Van Wering, G. E. Janka-Schaub, Monique Passier
Publikováno v:
Leukemia, 20, 1377-1384. Nature Publishing Group
The T-lineage phenotype of childhood acute lymphoblastic leukaemia (ALL) is associated with an increased relapse-risk and in vitro resistance to drugs as compared to a precursor B phenotype. Antiapoptotic isoforms of p73 that lack part of the transac
Autor:
Rob Pieters, M L den Boer, Stephen E. Sallan, G. E. Janka-Schaub, Monique Passier, Ronald W. Stam, Scott A. Armstrong
Publikováno v:
Leukemia, 20, 264-271. Nature Publishing Group
MLL rearranged acute lymphoblastic leukemia (MLL) is an aggressive type of acute lymphoblastic leukemia (ALL), diagnosed predominantly in infants (1 years of age). Since current chemotherapy fails in50% of patients with MLL, new therapeutic strategie
Autor:
Monique L. den Boer, Anne R. M. von Bergh, Rob Pieters, H. Berna Beverloo, Karin M. Kazemier, G. E. Janka-Schaub, Amy Holleman
Publikováno v:
Blood, 106(5), 1817-1823. American Society of Hematology
Drug resistance in childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) is associated with impaired ability to induce apoptosis. To elucidate causes of apoptotic defects, we studied the protein expression of Apaf-1, procaspas
Autor:
M L den Boer, Jochen Harbott, E. R. Van Wering, A H Loonen, Bruce M. Camitta, G. E. Janka-Schaub, Rosalyn Slater, W.-D. Ludwig, Rob Pieters, N L Ramakers-van Woerden, Anjo J.P. Veerman, H B Beverloo, Oskar A. Haas
Publikováno v:
Leukemia, 18(3), 521-9. Nature Publishing Group
Ramakers-van Woerden, NL, Beverloo, HB, Veerman, A J P, Camitta, BM, Loonen, A H, van Wering, E R, Slater, RM, Harbott, J, den Boer, M L, Ludwig, WD, Haas, OA & Janka-Schaub, GE 2004, ' In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. ', Leukemia, vol. 18, no. 3, pp. 521-9 . https://doi.org/10.1038/sj.leu.2403253
Leukemia, 18, 521-529. Nature Publishing Group
Ramakers-van Woerden, NL, Beverloo, HB, Veerman, A J P, Camitta, BM, Loonen, A H, van Wering, E R, Slater, RM, Harbott, J, den Boer, M L, Ludwig, WD, Haas, OA & Janka-Schaub, GE 2004, ' In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. ', Leukemia, vol. 18, no. 3, pp. 521-9 . https://doi.org/10.1038/sj.leu.2403253
Leukemia, 18, 521-529. Nature Publishing Group
Acute lymphoblastic leukemia (ALL) in infants under 1 year is strongly associated with translocations involving 11q23 (MLL gene), CD10-negative B-lineage (proB) immunophenotype, and poor outcome. The present study analyses the relationship between ag
Autor:
Yinmei Zhou, Martin Schrappe, Ching-Hon Pui, Giuseppe Masera, Lewis B. Silverman, M. G. Valsecchi, William E. Evans, S Richards, Susana C. Raimondi, Nyla A. Heerema, Etienne Vilmer, Andrea Biondi, André Baruchel, Bruce M. Camitta, Jeanette Pullen, G. E. Janka-Schaub, Harland Sather, Christine J. Harrison, Jonathan J. Shuster, Stephen E. Sallan, Jochen Harbott, JM Chessells, D. Harms, Willem Kamps, Helmut Gadner, Paul S. Gaynon, Patricia L. Harrison, OB Eden, H. Riehm, James M. Boyett, Andrew J. Carroll
Publikováno v:
Leukemia, 17(4), 700-706. Nature Publishing Group
To assess the clinical heterogeneity among patients with acute lymphoblastic leukemia (ALL) and various 11q23 abnormalities, we analyzed data on 497 infants, children and young adults treated between 1983 and 1995 by 11 cooperative groups and single
Autor:
Marianne G. Rots, Mats Heyman, Willem Kamps, Rob Pieters, E van Drunen, A H Loonen, H B Beverloo, N. L. Ramakers-Van Woerden, TC Moreno, E. R. Van Wering, G. E. Janka-Schaub, Rosalyn Slater, A. J. P. Veerman
Publikováno v:
British Journal of Haematology. 112:680-690
p16 gene deletions are present in about 70% of primary paediatric T-cell acute lymphoblastic leukaemia (T-ALL) and 20% of common/precursor B-cell ALL cases. It is not clear what the impact of the frequent p16 deletions is within the subgroup of T-lin
Autor:
Marianne G. Rots, A. J. P. Veerman, Rob Pieters, P. Noordhuis, Günter Henze, G. E. Janka-Schaub, G.J. Peters, Gerrit Jansen, C. H. Van Zantwijk
Publikováno v:
British Journal of Haematology. 109:629-634
Treatment failure in childhood acute lymphoblastic leukaemia (ALL) might be associated with methotrexate (MTX) resistance. Little is known about MTX resistance in relapsed ALL. In this study, we determined ex vivo MTX resistance in precursor-B ALL at